Endogenous Ligands of Imidazoline Receptors: Classic and Immunoreactive Clonidine‐Displacing Substance and Agmatine

Annals of the New York Academy of Sciences

Volumn 763, Issue 1, 1995, Pages 295-313

  REIS, DONALD J ^a   LI, GEN ^a   REGUNATHAN, SOUNDARARAJAN ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; CLONIDINE DISPLACING SUBSTANCE; IMIDAZOLINE RECEPTOR; RECEPTOR SUBTYPE; RILMENIDINE;

ADRENAL GLAND; ARTERIAL PRESSURE; BINDING AFFINITY; BRAIN CORTEX; CONFERENCE PAPER; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOREACTIVITY; KIDNEY; LIGAND BINDING; MATERNAL HYPERTENSION; MOLECULAR WEIGHT; NONHUMAN; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STOMACH FUNDUS;

EID: 0029145740     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1995.tb32416.x     Document Type: Article

References (89)

1. Cardiovascular regulation by central adrenergic mechanisms and its alteration by hypotensive drugs
2. Differentiation of drugs acting centrally upon the cardiovascular system by means of sympathetic and vagal responses
3. Imidazoline receptors: Historical perspective
4. Possible involvement of central histamine H2‐receptors in the hypotensive effect of clonidine
5. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines
6. Alpha‐adrenergic drugs. Pharmacological tools for the study of the central vasomotor control
7. Imidazole receptors and clonidine‐displacing substance in relationship to control of blood pressure, neuroprotection and adrenomedullary secretion
8. Sympathoexcitatory neurons of the rostral medulla are oxygen sensors and essential elements in the tonic and reflex control of the systemic and cerebral circulations
9. 2‐adrenoceptors in the ventrolateral medulla
10. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla
11. Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area
12. Ventrolateral medullary pressor area: Site of hypotensive action of clonidine
13. 1‐imidazoline sites
14. 3H‐idazoxan in rat brain
15. 2‐adrenergic antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine, and corynanthine
16. High affinity binding of idazoxan to a non‐catecholaminergic binding site in the central nervous system: Description of a putative idazoxan receptor
17. Further characterization of the guinea pig cerebral cortex idazoxan receptor: Solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor‐selective drug
18. Keeping an eye on the I site: Imidazoline‐preferring receptors
19. Imidazoline‐guanidinium receptive site in renal proximal tubule: Asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance
20. Characterization of imidazoline‐guanidinium receptive sites in renal medulla from human kidney
21. Development of a high‐affinity radioiodinated ligand for identification of imidazoline/guanidinium receptive sites (IGRS): Intratissue distribution of IGRS in liver, forebrain, and kidney
22. 2‐adrenergic receptor activity
23. 2‐adrenoceptors
24. Characterization of mitochondrial imidazoline‐guanidinium receptive sites (IGRS) in liver
25. Identification of an imidazoline‐guanidinium receptive site in mitochondria from rabbit cerebral cortex
26. Characterization and autoradiographical localization of non‐adrenoceptor idazoxan binding sites in the rat brain
27. Imidazoline receptors in the nervous system
28. 2‐adrenoceptors in the human central nervous system
29. Protection of focal ischemic infarction by rilmenidine in the animal: Evidence that interactions with central imidazoline receptors may be neuroprotective
30. Expression of non‐adrenergic imidazoline sites in rat cerebral cortical astrocytes
31. 2‐adrenergic receptors
32. 3H‐diazoxan in rabbit urethral smooth muscle
33. Nonadrenergic imidazoline binding sites on human platelets
34. 2‐adrenoceptors and of non‐adrenergic idazoxan binding sites in pancreatic islets from young and adult hamsters
35. 2D‐adrenoceptor and nonadrenergic idazoxan‐binding sites
36. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non‐adrenoceptor idazoxan binding sites
37. Imidazoline binding sites in human placenta: Evidence for heterogeneity and a search for physiological function
38. Effects of clonidine and other imidazoline‐receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells
39. + transport and intracellular pH in renal proximal tubule cells
40. Block of ATP‐regulated potassium channels by phentolamine and other alpha‐adrenoceptor antagonists
41. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels
42. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase
43. Isolation and partial purification of a clonidine‐displacing endogenous brain substance
44. Isolation of an endogenous clonidine‐displacing substance from rat brain
45. Isolation of clonidine‐displacing substance from bovine brain: Functional characterization
46. An endogenous clonidine‐displacing substance from bovine brain: Receptor binding and hypotensive actions in the ventrolateral medulla
47. An endogenous substance with clonidine‐like receptor binding selectivity: The brain's own clonidine
48. An endogenous substance with clonidine‐like properties: Selective binding to imidazole sites n the ventrolateral medulla
49. Agmatine is an endogenous clonidine‐displacing substance in brain
50. 2‐adrenergic receptor activity
51. 2‐adrenergic receptor
52. Clonidine‐displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells
53. Raised levels of an endogenous nonadrenergic substance in the serum of pregnancy‐induced hypertension patients
54. Detection and measurement of an endogenous clonidine‐displacing substance in human cerebrospinal fluid
55. Neuroblastoma‐glioma hybrid cells contain clonidine‐displacing substance
56. 2‐adrenoceptors of human platelets
57. An endogenous brain substance, CDS (clonidine‐displacing‐substance), inhibits the twitch response of rat vas deferens
58. Human plasma‐derived material with clonidine displacing substance (CDS)‐like properties contracts the isolated rat aorta
59. Clonidine displacing substance is biologically active on smooth muscle
60. An endogenous, non‐catecholamine clonidine antagonist increases mean arterial blood pressure
61. Polyclonal antiserum to a para‐aminoclonidine conjugate recognizes an endogenous clonidine‐like substance(s) in brain
62. A specific antiserum recognizes clonidine‐displacing substance: Implications for the structure of the brain's own clonidine
63. Clonidine‐specific antisera recognize an endogenous clonidine‐displacing substance in brain
64. Idazoxan‐specific antiserum recognizes an endogenous clonidine‐displacing substance (CDS) in human serum and CSF
65. A polyclonal antibody raised against clonidine: A model for the specific imidazoline receptor
66. Production and characterization of anti‐clonidine antibodies not cross‐reacting with catecholamines
67. Production and characterization of an iminoimidazolidine specific monoclonal antibody using para‐aminoclonidine as antigen
68. A circulating substance cross‐reacting with antiimidazoline antibodies. Detection in serum in relation to essential hypertension
69. Clonidine‐displacing substance is present in peripheral tissues of the rat
70. Evidence for a bioactive clonidine‐displacing substance in peripheral tissues and serum
71. An antibody to agmatine localizes the amine in bovine adrenal chromaffin cells
72. Regional distribution of agmatine and arginine decarboxylase in rat brain
73. Polyamines
74. Transmitter sensitivity of neurons assayed by autoradiography
75. Inhibition of nicotinic receptor mediated ion fluxes in rat sympathetic ganglia by BGT II‐S1, a potent phospholipase
76. Evidence for an involvement of membrane lipids in the control of neuronal nicotinic receptor function using bungarotoxin II‐S1
77. Autoradiographic measurement of tritiated agmatine as an indicator of physiologic activity in Hermissenda visual and vestibular neurons
78. Agmatine acts as an antagonist of neuronal nicotinic receptors
79. Stimulus‐secretion coupling of arginine‐induced insulin release. Insulinotropic action of agmatine
80. Insulin‐like partial effects of agmatine derivatives in adipocytes
81. Insulin‐like effects of agmatine derivatives in vitro and in vivo.
82. Cardiovascular responses to agmatine, a clonidine‐displacing substance, in anesthetized rats
83. Clonidine acts on imidazole receptors in brain which bind an endogenous clonidine‐displacing substance